Next Article in Journal
Subcellular Localization and Mitotic Interactome Analyses Identify SIRT4 as a Centrosomally Localized and Microtubule Associated Protein
Next Article in Special Issue
Playing Jekyll and Hyde—The Dual Role of Lipids in Fatty Liver Disease
Previous Article in Journal
Loganin Attenuates High Glucose-Induced Schwann Cells Pyroptosis by Inhibiting ROS Generation and NLRP3 Inflammasome Activation
Previous Article in Special Issue
MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 9
Issue 9
10.3390/cells9091949
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice

by
Luisa Hahn
1,
Nora Helmrich
1,
Diran Herebian
2,
Ertan Mayatepek
2,
Uta Drebber
3,
Eugen Domann
4,
Stefan Olejniczak
4,
Markus Weigel
4,
Torsten Hain
4,
Timo Rath
5,
Stefan Wirtz
5,
Hans-Joachim Mollenkopf
6,
Nadine Schmidt
7,
Christa Ewers
7,
Anne Baier
1,
Yuri Churin
1,
Anita Windhorst
8,
Ralf Weiskirchen
9,
Ulrich Steinhoff
10,
Elke Roeb
1,† and
Martin Roderfeld
1,*,†add Show full author list remove Hide full author list
1
Department of Gastroenterology, Justus-Liebig-University, D-35392 Giessen, Germany
2
Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich-Heine-University, D-40225 Duesseldorf, Germany
3
Institute for Pathology, University Hospital of Cologne, D-50937 Cologne, Germany
4
Institute of Medical Microbiology, German Centre for Infection Research (DZIF Partner Site Giessen-Marburg-Langen), Justus-Liebig-University, D-35392 Giessen, Germany
5
Department of Medicine 1, Division of Gastroenterology, Pneumology and Endocrinology, Friedrich-Alexander University Erlangen-Nuremberg, D-91054 Erlangen, Germany
6
Core Facility Microarray, Max Planck Institute for Infection Biology, D-10117 Berlin, Germany
7
Institute of Hygiene and Infectious Diseases of Animals, Justus-Liebig-University Giessen, D-35392 Giessen, Germany
8
Institute for Medical Informatics, Justus-Liebig-University, D-35392 Giessen, Germany
9
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital, RWTH Aachen University, D-52074 Aachen, Germany
10
Institute for Medical Microbiology and Hospital Hygiene, Philipps University Marburg, D-35043 Marburg, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cells 2020, 9(9), 1949; https://doi.org/10.3390/cells9091949
Submission received: 9 July 2020 / Revised: 19 August 2020 / Accepted: 20 August 2020 / Published: 24 August 2020
(This article belongs to the Special Issue Cellular and Molecular Mechanisms underlying the Pathogenesis of Hepatic Fibrosis II)
Browse Figures
Review Reports Versions Notes

Abstract

:
The Th2 cytokine IL-13 is involved in biliary epithelial injury and liver fibrosis in patients as well as in animal models. The aim of this study was to investigate IL-13 as a therapeutic target during short term and chronic intrahepatic cholestasis in an Abcb4-knockout mouse model (Abcb4−/−). Lack of IL-13 protected Abcb4−/− mice transiently from cholestasis. This decrease in serum bile acids was accompanied by an enhanced excretion of bile acids and a normalization of fecal bile acid composition. In Abcb4−/−/IL-13−/− double knockout mice, bacterial translocation to the liver was significantly reduced and the intestinal microbiome resembled the commensal composition in wild type animals. In addition, 52-week-old Abcb4−/−IL-13−/− mice showed significantly reduced hepatic fibrosis. Abcb4−/− mice devoid of IL-13 transiently improved cholestasis and converted the composition of the gut microbiota towards healthy conditions. This highlights IL-13 as a potential therapeutic target in biliary diseases.

1. Introduction

Bile ducts are involved in the formation and secretion of bile, as well as in the excretion of circulating xenobiotic substances. The intrahepatic biliary epithelium represents a barrier to diffusion of toxic substances and microbes from the bile into the interstitial hepatic tissue. Thus, the preservation of intact biliary epithelium is essential for the maintenance of its barrier function [1]. Clinically, biliary epithelial cell (BEC) barrier dysfunction is involved in the development and perpetuation of biliary diseases [2,3]. Alterations in tight junctions play a role in BEC barrier dysfunction and bile duct leakiness [4]. As a consequence, leaky intrahepatic bile ducts can cause parenchymal damage by releasing toxic bile acids (BA) and lipopolysaccharides (LPS) [2,5] into the interstitial tissue, subsequently causing inflammation and fibrosis [6].
In addition, the leaky gut hypothesis suggests that intestinal bacteria and bacterial products can translocate from the permeable gut via the portal vein into the liver. By triggering hepatic inflammation and fibrosis, a leaky gut further contributes to the progression of chronic liver disease [7]. Especially in intrahepatic cholestasis during pregnancy, a leaky gut is assumed to be involved in the hepatic pathogenesis [8]. In this context, the gut microbiota have also been claimed to be crucially involved in the pathophysiology of chronic liver diseases [9,10]. Most recently, it has been demonstrated that cholestasis changes the intestinal microbiome composition of mice, which partially resembles the observations described during human cholestasis [11].
The detergent properties of BAs are able to disrupt cell membranes and to promote the generation of reactive oxygen species. As a consequence, oxidation of lipids, proteins, and nucleic acids might cause hepatocyte necrosis and apoptosis [12].
Pro-inflammatory Th1 cytokines, such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), are induced in primary sclerosing cholangitis, PSC, and biliary atresia [13,14]. These Th1 cytokines have the potential to disrupt the epithelial barrier function in cultured cholangiocytes from rodents [15,16]. In addition, Th2 cytokines, such as interleukin (IL)-4, IL-5, and IL-13, are increased in sclerosing cholangitis and play a crucial role in the desintegration of tight junction-mediated BEC barrier [17,18]. Moreover, the release of high amounts of IL-13 from type 2 innate lymphoid cells has been shown to promote hyperplasia of cholangiocytes [19]. Beyond the cytokine function in initial damage of the bile duct epithelium, a dysregulated balance of Th1 and Th2-mediated signals determines the outcome of chronic liver diseases [20]. In particular, IL-13 is able to promote hepatic fibrogenesis of different etiologies and has been identified as a major pathogenic cytokine in helminth-induced liver disease [21,22,23,24]. However, the precise functional role of IL-13 in the development of chronic cholestasis remains to be established. In this study, we carefully analyzed the impact of IL-13 knockout on liver pathology and intestinal microbiome in Abcb4 knockout mice.

2. Materials and Methods

2.1. Animal Model

Transgenic mice were maintained at the Central Animal Laboratory of the Justus-Liebig-University Giessen, Germany under specified pathogen-free conditions. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the German law of animal welfare. Mice received humane care, and all experiments were approved by the Committee on the Ethics of Animal Experiments of the Regierungspräsidium Giessen, Giessen, Germany (permit number: V54-19c 20 15 h 01 GI20/10 No. A29/2013 and No. 128/2014). Handling and holding conditions were described previously [25]. All efforts were made to minimize suffering.
Mice were analyzed for the presence of antibodies against several mouse pathogens known to be associated with liver disease, including mouse hepatitis virus, Sendai virus, ectromelia virus, reovirus 3, and lymphocytic choriomeningitis virus, by mfd Diagnostics (Wendelsheim, Germany).
Generation and characteristics of knockout lineages C.FVB(129P2)-Abcb4tm1Bor (Abcb4−/−) and BALB/c-ll13tm2Anjm (IL-13−/−) have been described previously [26,27,28]. Abcb4−/− and IL-13−/− mice on BALB/c background were crossed to raise double-knockout hybrids C.Cg-ll13tm2Anjm-Abcb4tm1Bor (Abcb4−/−/IL-13−/−). BALB/c WT littermates were bred from heterozygous F1 during crossbreeding to raise double-knockout hybrids. All animals in this study were bred in a single colony. At the age of 8, 26, and 52 weeks, mice were anaesthetized by isoflurane inhalation and subsequently killed by cervical dislocation. Liver samples were collected and preserved for analyses. Liver weight (LW) to body weight (BW)% ratio was calculated.

2.2. Routine Serum Biochemistry

Blood was collected from the vena cava. Enzymatic assays were used to measure alanine aminotransferase (ALT) as well as alkaline phosphatase (AP) on a Reflotron Plus Analyzer (Roche Diagnostics, Mannheim, Germany).

2.3. Histology

Sections of formalin-fixed and paraffin-embedded liver tissue were prepared and stained with hematoxylin and eosin or Sirius red. The histology of specimens was independently assessed by a pathologist specialized in hepatology (U.D.) and scored as described [29]. Briefly, portal inflammation, fibrosis, ductular reaction, mitotic activity, and Councilman bodies were scored in four grades (0–3).

2.4. Immunohistochemistry/Immunofluorescence

Detection of the cholangiocyte marker cytokeratin 19 (Santa Cruz Biotech., Santa Cruz, CA, USA, cat# sc-33111, RRID:AB_2234419), adhesion-marker E-Cadherin (Abcam, Berlin, Germany, cat# ab11512, RRID:AB_298118), tight-junction marker ZO-1 (Novus Biologicals, Bio-Techne GmbH, Wiesbaden, Germany, cat# NBP1-85047, RRID:AB_11023321), Ki67 (Abcam, cat# ab27619, RRID:AB_471081), SOX9 (Santa Cruz Biotech., cat# sc-20095, RRID:AB_661282), c-Jun (Cell Signaling Technology, Frankfurt am Main, Germany, cat# 9165, RRID:AB_2130165), and CD3 (Abcam, cat# ab16044, RRID:AB_443294) was performed as described [27].

2.5. Bile Acid Analysis

Bile acids were quantified by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), as has been described in the literature [30]. Bile acids from feces were extracted as described before [31].

2.6. Western Blot Analysis

Protein samples were prepared from total liver lysates. Protein samples were boiled in Lämmli-buffer for 5 min, chilled on ice, and subjected to 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Visualization of proteins was performed by horseradish-peroxidase (HRP)-linked antibodies. ECL Chemiluminescence Detection Kit (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific, Darmstadt, Germany) was used according to the manufacturer’s protocol.

2.7. Transcriptome Microarray and Gene Set Analysis

Microarray analysis was performed with total RNA from the liver of 8-week-old mice as described previously [32]. The data presented here have been deposited in NCBI’s Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/, RRID:SCR_004584) and are accessible through GEO Series accession number GSE90995. p-values less than 0.01 and twofold changes were defined as the cut-off criteria. Functional annotation clustering of the large lists of genes that were regulated was performed using the Database for Annotation, Visualization and Integrated Discovery at default settings (DAVID 6.8, RRID:SCR_001881) [33] and Kyoto Encyclopedia of Genes and Genomes (KEGG, RRID:SCR_012773) [34].

2.8. Bacterial Translocation to the Liver

Homogenates of 50mg liver tissue were filtered using a cell strainer (100 μm pore size; Corning, Tewksbury, MA 01876 USA) and serial dilutions were plated onto a blood agar plate (Thermo Scientific™ Oxoid™, Fisher Scientific, Wesel, Germany), brain heart infusion (BHI) agar (Thermo Scientific™), and water-blue metachrome-yellow lactose agar (acc. to Merck KGaA, Darmstadt, Germany). Additionally, Schaedler agar (Becton Dickinson GmbH, Heidelberg, Germany) was used for anaerobic growth examination in an anaerobic jar system (AnaeroGen™; Thermo Scientific™ Oxoid™, Fisher Scientific, Oxford, OX14 4SD, UK) after 72 h of incubation at 37 °C. For enrichment purposes, each sample was inoculated to nutrient broth no. 2 containing 10% bovine serum and broth were streaked onto blood, BHI and Schaedler agar plate after 24 h incubation at 37 °C. Plates were examined after 24 and 48 h, as well as for BHI and Schaedler agar after 72 h at 10% CO2. Morphologically diverse colonies were sub-cultivated. Pure cultures were identified using MALDI-TOF MS (Biotyper Version V3.3.1.0, Bruker Daltonics, Bremen, Germany) by the direct smear method and information provided in the DB7311 database. The MALDI-TOF results were supported by the Gram stain method and morphological properties of the bacteria.

2.9. Quantitative Real-Time PCR

RNA isolation, complementary DNA synthesis and real-time PCR were performed as described previously [35]. Oligonucleotide sequences are available upon request. We used 18S ribosomal RNA as housekeeping control.

2.10. Hepatic Hydroxyproline Ccontent

To quantify liver fibrosis, hepatic hydroxyproline was measured as described previously [36].

2.11. 16 SrDNA Sequencing forMicrobiome Profiling

Mouse feces was collected in sterile 1.5 mL Eppendorf tubes, weighted, and filled-up with 0.9% NaCl in order to adjust a concentration of 0.1 g/mL. The samples were extensively vortexed and DNA was extracted by using glass beads and the Power Lyzer DNA Isolation Kit from MoBio as recommended by the vendor (MoBio Laboratories, Carlsbad, CA, USA). DNA was eluted with 100 µL of DNase-free water and concentration was determined using Qubit Fluorometric Quantitation (Thermo Fisher Scientific, Waltham, MA, USA). The V4 region of 16S rRNA gene was amplified using adapter forward primer 5′-TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG GTG CCA GCM GCC GCG GTA A-3′, adapter reverse primer 5′-GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA GGG ACT ACH VGG GTW TCT AAT-3′ and the 2 × Kapa HiFi HotStart Ready Mix (Kapa Biosystems, Wilmington, MA, USA). The amplification profile comprised an initial heating step at 95 °C for 30 s, 25 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s, elongation at 72 °C for 30 s, and a final elongation step at 72 °C for 5 min. PCR products were purified with Agencourt AMPure XP system as recommended by the vendor (Beckman Coulter, Brea, CA, USA). The size, purity, and concentration of amplicons were determined using the Agilent Bioanalyzer as recommended by the vendor (Agilent Technologies, Santa Clara, CA, USA). The index PCR was done using the Nextera index Kit v2 Set B as recommended by the vendor (Illumina, San Diego, CA, USA). The quality of the index PCR was determined as described above for the adapter PCR. The library was adjusted to 3 pM, the flow cell was prepared and loaded according to the Reagent Preparation Guide of MiSeq Reagent Kit v2 as recommended by the vendor (Illumina) and sequenced using Illumina’s MiSeq device.

2.12. Bioinformatics Workflow

MiSeq software version 2.6 was used to split the sequences by barcode and to generate the fastq files. The microbiome analysis was done following the MiSeq Soap [37] using Mothur version 1.36.1 [37]. For the alpha and beta diversity calculation and the taxa summary plots, Qiime version 1.9.1 [38] was used. The paired end reads were joined, and the primer sequences were removed. We filtered for the expected amplicon length and removed reads with ambiguous base calls or with homopolymers longer the eighth nucleotides. Duplicate sequences were merged. The unique reads were aligned against the SILVA-bases bacterial reference alignment [39]. Nucleotides outside the expected alignment region were trimmed. Reads with a difference of two nucleotides were merged during pre-clustering. Chimeric reads were removed using the Mothur implementation of the UCHIME algorithm [40]. After chimera removal, the taxonomy was assigned and non-bacterial reads were discarded. The Operational taxonomic units (OTUs) were created using the cluster split method of Mothur. After clustering, we reassigned the taxonomy to the OTUs. In preparation for the analysis with Qiime, a phylogenetic tree and an OTU table in biom format were created. Alpha and beta diversity analysis and the taxa summery plots were created using the Qiime core diversity analysis script.

2.13. Statistical Analysis

Statistical analysis was performed with SPSS V. 22.0 software (SPSS Inc.). The significance of the data was determined by Kruskal–Wallis tests and subsequent Mann–Whitney U tests as well as bivariate Spearman’s rank tests and, the results were considered significant at p < 0.05. Sparse partial least squares discriminant analysis (sPLSDA) was conducted with R (Version 3.1.1) and the mixOmics R-package (version 6.0.0). The method sPLSDA is based on classical partial least squares regression and was used for classification and discrimination problems. In addition, sPLSDA allows variable selection. Here, we used sPLSDA to discriminate between the different mouse lines by their microbiome. For network analysis, the strongest relationships between strains from the microbiome and mouse strains are depicted. The threshold is set at an absolute association value of 0.51. The heatmap gives a representation of the similarity matrix between mouse lines, as well as between strains of the microbiome. A hierarchical clustering is applied to mouse lines, as well as to strains of the microbiome. The results of the hierarchical clustering are depicted in dendrograms at the sides of the heatmap.

3. Results

3.1. IL-13 Knockout Restored Intrahepatic Bile Duct Integrity and Biliary Epithelial Cell Barrier Function in Abcb4−/− Mice

Livers of Abcb4−/− mice showed distorted bile canaliculi and areas of dilatation, while the morphology of BEC and the bile ducts was preserved in Abcb4−/−/IL-13−/− mice (Figure 1A). In detail, loss of lumenization or bile duct collapse (arrowhead), proliferation of biliary cells (arrows), thickening of the mesenchymal layer (brackets), swelling of BEC, and altered BEC organization were ameliorated in Abcb4−/−/IL-13−/− mice (Figure 1A). However, elderly Abcb4−/−/IL-13−/− mice (52 weeks) showed the same pattern of perturbed intrahepatic bile duct architecture as Abcb4−/− mice (lower right panels of Figure 1A). Since loss of epithelial barrier function has been identified to cause regurgitation of bile acids from leaky bile ducts in Abcb4−/− mice [4], we analyzed the expression of tight junctions via immunofluorescence staining of E-cadherin and ZO-1. Cell–cell contacts between BECs were intact in 8-week-old Abcb4−/−/IL-13−/− mice, but not in age-matched Abcb4−/−, illustrating that barrier function is preserved upon the genetic deletion of IL-13 in Abcb4−/− mice (Figure 1B,C). In order to determine proliferation and differentiation of BECs, Ki67 and SRY-related HMG box transcription factor 9 (Sox9) were immunohistochemically analyzed in combination with the BEC-marker, CK19 (Figure 1D,E).
While proliferation was a rare event in BECs of controls and in Abcb4−/−/IL-13−/− mice, approx. 50% of BECs stained positive for Ki67 in Abcb4−/− mice, indicating that IL-13 knockout reduced biliary proliferation in Abcb4−/− mice (Figure 1D and Figure S1). Biliary Sox9 was only marginally expressed in Abcb4−/− mice while BECs of controls and Abcb4−/−/IL-13−/− mice strongly expressed Sox9, which is important for bile duct morphogenesis and cholangiocyte polarity [41] (Figure 1E). Regurgitation of bile acids from leaky bile ducts is the pathological key event leading to enhanced hepatic- and serum BA concentrations that finally cause hepatobiliary disease in Abcb4−/− mice [4].
Consistent with the preserved barrier function in Abcb4−/−/IL-13−/− mice, quantitative analysis of serum bile acids in these mice revealed a ten-fold decrease compared to Abcb4−/− (p = 0.014, Figure 2A, significances between Abcb4−/−- and Abcb4−/−/IL-13−/−-groups are highlighted). Furthermore, analysis of the seven most prominent BAs revealed a significant decline in each BA in double knockout mice compared to Abcb4−/− mice (Figure 2B). Unconjugated and glycine-conjugated BAs represented less than 5% of the total serum-bile acid pool in both, Abcb4−/− and Abcb4−/−/IL-13−/− mice (not shown).

3.2. Reduced Serum BA Improved Liver Integrity

Although Abcb4−/−/IL-13−/− mice exhibit the same phenotype with respect to appearance, fertility, survival, body and liver weight as Abcb4−/− controls, we observed 1.7- and 1.6-fold reduced serum ALT levels in 8- and 26-week-old Abcb4−/−/IL-13−/− mice, respectively (Figure 2C). As serum ALT correlated with serum BA concentrations, we suggest that biliary destruction precedes chronic liver injury (ρ = 0.839, p < 0.001, Figure 2D). In order to define the impact of IL-13 on bile acid composition, the ratio of secondary to primary BAs and the hydrophobicity index were calculated by a modified Heuman’s method (Figure 2E,F) [42,43]. Surprisingly, the characteristic ratio of secondary to primary BA, which is specific for liver damage, was not altered in 8-week-old IL-13 deficient Abcb4−/− mice (Figure 2E). However, the hydrophobicity index (HI) of serum BA was reduced in 8-week-old Abcb4−/− mice as compared to wild type controls, indicating increased hydrophilic BAs (p = 0.014, Figure 2F). Most importantly, HI became normal in Abcb4−/−/IL-13−/− animals. Neither alkaline phosphatase (Figure S2) nor the expression of genes responsible for BA synthesis and transport, as well as hepatic inflammation, were altered in Abcb4−/−/IL-13−/− mice, as compared to Abcb4−/−-controls (Figure S3). Interestingly, ER-stress-associated PERK and eIF2α were phosphorylated in Abcb4−/− mice, while this phosphorylation pattern was reduced in Abcb4−/−/IL-13−/− mice (Figure S4).

3.3. Lack of IL-13 Reduces Hepatic Pathology and Fibrosis

IL-13-devoid Abcb4−/− mice had a reduced histological score with decreased numbers of apoptotic hepatocytes in 8-week-old animals (Figure 3A,B). Despite reduced expression of the proliferation marker Ki67 in Abcb4−/−/IL-13−/− mice, histological assessment of ductular proliferation did not show significant changes (Figure 3C). Hepatic fibrosis was clearly reduced in 52-week-old Abcb4−/−/IL-13−/− mice (p = 0.002, Figure 3D,E). ALT was highly correlated with HYP as a marker of fibrogenesis (Figure 3F).

3.4. IL-13 Alters Hepatic Gene Expression

In order to investigate the impact of IL-13 on gene regulation, we performed an RNA-array from the livers of Abcb4−/− mice and Abcb4−/−/IL-13−/− mice. IL-13 depletion caused changes in the expression pattern of genes as compared to the livers of IL-13-proficient Abcb4−/− mice. Numerous transcripts were regulated more than two-fold with p < 0.05 in Abcb4−/− mice as compared to Abcb4−/−IL-13−/− mice (749 vs 569, respectively). Functional annotation clustering revealed biological processes that are crucially involved in the development of cholestasis in Abcb4−/− mice (Table 1). For example, genes related to cell adhesion and ECM receptor interaction are likely to be involved in the modulation of BEC barrier function, while genes related to the extracellular matrix are linked to fibrogenesis.
Of note, UDP glucuronosyltransferase 2 B37 (Ugt2b37) and Cyp26 encoding for enzymes involved in retinoic acid and estrogen clearance were strongly upregulated in Abcb4−/− and suppressed in Abcb4−/−/IL-13−/− mice. On the other hand, genes involved in metabolite biosynthesis and transport such as Cyp3a41b and Cyp3a44 were strongly reduced in Abcb4−/− and induced in Abcb4−/−/IL-13−/− mice. A similar regulation was observed for genes related to the PPAR signaling pathway, including members of the Cyp4a12 family (involved in blood pressure) but also fatty acid binding proteins, involved in fatty acid transport and lipid accumulation in the liver. Thus, global gene analysis identified many genes that directly or indirectly are involved in IL-13-regulated biliary pathology. Nevertheless, array analysis and functional annotation clustering did not demonstrate different regulation of BA transporters and pumps between Abcb4−/− and Abcb4−/−/IL-13−/− mice. The data presented here have been deposited in NCBI’s Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/, RRID:SCR_004584) and are accessible through GEO Series accession number GSE90995.

3.5. Lack of IL-13 Alters Bile Acid Excretion Patterns, Improves Ileal Integrity, and Reduces Bacterial Translocation

The observation of strongly reduced serum BA concentrations but unaltered BA synthesis and BA transport raised the question if the composition of excreted bile acids was also modified in Abcb4−/−/IL-13−/− mice. Quantitative analysis of BAs in feces revealed an entirely modified composition of excreted BAs (Figure 4A). While β-muricholate (β-MCA, p = 0.018) and deoxycholate (DCA, p = 0.018) are the major BAs excreted by Abcb4−/− mice, we observed that the diversity of excreted BAs was by far bigger in Abcb4−/−/IL-13−/− mice (Figure 4A). α-MCA (p = 0.006) and β-MCA were predominantly found in the feces of Abcb4−/−/IL-13−/− mice. Interestingly, hydrophilic Hyodeoxycholic acid (HDCA) was one of the major BAs excreted by double knockout mice (p = 0.006, Figure 4A).
The ratio of excreted serum BAs was increased eight-fold (p = 0.006) in Abcb4−/−/IL-13−/− mice, while the total amount of BAs excretion was not altered by IL-13 depletion in Abcb4−/− mice (Figure 4B). The ratio of secondary to primary BAs and hydrophobicity index were reduced in Abcb4−/−/IL-13−/− mice (p = 0.018, Figure 4C,D). With the knowledge that BAs with increased hydrophobicity display enhanced toxicity [44,45], we next studied the ileal histopathology of IL-13-proficient and -deficient Abcb4−/− mice (Figure 4E and Figure 5). In Abcb4−/− mice, blunting and crippledness of villi as well as loss of goblet cells indicated intestinal pathology (Figure 4E). Separation of the villus epithelium from the underlying lamina propria indicated pronounced interstitial edema (stars, Figure 4E). These pathological alterations were less pronounced in Abcb4−/−/IL-13−/− mice (upper right panel Figure 4E). Similarly, inconsistent and reduced expression of E-cadherin as well as enhanced c-Jun expression was normalized in Abcb4−/−/IL-13−/− mice (middle and lower panels, Figure 4E). Furthermore, epithelial proliferation and lymphocyte infiltration were close to normal in Abcb4−/−/IL-13−/− mice (Figure S5). An overview of the histological alterations is shown in Figure S5C–E. Furthermore, we analyzed bacterial translocation to the liver, which has also been observed in other models of cholestasis [46]. Bacterial translocation to the liver was reduced in Abcb4−/−/IL-13−/−-mice. (Figure S6).

3.6. IL-13 Depletion is Associated with Profound Compositional Changes in Gut Microbiota

Altered BA composition in feces and ileal integrity raised the question whether the intestinal microbiome was also affected in IL-13 deficient mice. 16S RNA sequencing revealed that IL-13 impacted the composition of the intestinal microbiome in Abcb4−/− mice (Figure 5A). Sparse partial least-square discriminant analysis revealed characteristic and group specific composition of fecal microbiomes (Figure 5B). For example, bacteria belonging to the families of Prevotellaceae and Oscillibacter were overrepresented in Abcb4−/− mice and normalized in Abcb4−/−/IL-13 knockout, while Lactobacillae, Roseburia, Alistipes, and Incertae Sedis were increased in Abcb4−/−/IL-13−/− mice (Figure 5C–E and Figure 6).

4. Discussion

Impaired bile formation or flow is the precondition for cholestatic liver diseases which can lead to chronic liver injury and end-stage liver disease. It has been demonstrated that the regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis [4]. The Th2-specific cytokine IL-13 is involved in the disruption of the BEC barrier in patients with IgG4-related cholangitis [17] and promoted cholangiocyte hyperplasia [19]. On the other hand, a Th1-shift improved cholestasis in Abcb4−/− mice [27]. In the present study, we analyzed the effect of IL-13 on cholestasis and on the intestinal microbiome in Abcb4−/− mice and found that the absence of IL-13 improved cholestasis and hepatic fibrosis in Abcb4−/− mice. Further, IL-13 deficient Abcb4−/− mice revealed normal composition of bile acids, restored intestinal integrity, and preservation of commensal intestinal microbiota.
Abcb4−/− mice represent a well-characterized model for chronic cholestatic liver diseases [4]. Biliary injury and subsequent progressive injury of hepatic parenchyma result from defective biliary phospholipid (PL) secretion and subsequent increase in free non-micellar and toxic BA concentrations [4]. Loss of epithelial barrier function in Abcb4−/− mice is due to disturbed expression of tight junctions, altered basement membranes, and abnormally widened intercellular spaces of BECs [4]. Our data show profound alterations of intercellular BEC junctions in Abcb4−/− mice, indicated by altered expression pattern of E-cadherin and zonula occludens-1 (ZO-1). E-cadherin and ZO-1 play an important role in the maintenance of epithelial cell polarity and exhibit selective permeability to molecules with respect to their charge and size [1,47,48,49]. The loss of intercellular BEC junctions in Abcb4−/− mice was almost normalized in Abcb4−/−/IL-13−/− mice, which is in line with studies showing the disruption of the tight junction-associated BEC barrier by Th2 signals in cholangitis and biliary atresia [17,50]. Additionally, IL-13 reduced tight junction-associated BEC barrier function [17] as well as epithelial hyperplasia and biliary repair in vitro [19]. In agreement with these findings, we found that proliferation of BEC was reduced in Abcb4−/−/IL-13−/− animals as compared to Abcb4−/−-controls. Furthermore, while the biliary protein Sox9 was barely detectable in Abcb4−/− mice, normal expression was seen in Abcb4−/−/IL-13−/− mice. Lack of biliary proliferation and sustained Sox9 expression, both of which are required for bile duct morphogenesis and cholangiocyte polarity [41], demonstrates that IL-13 is essentially involved in the ductular reaction of Abcb4−/− mice. Functional clustering of regulated genes further supports the role of IL-13 to interfere with the integrity of ductular cells. In Abcb4−/−/IL-13−/− mice, the protective effect was associated with a 10-fold reduction in toxic serum-bile acid concentrations [51]. Thus, reduced serum ALT and improved pathological scoring clearly demonstrate preserved hepatic integrity.
Interestingly, the beneficial effects of IL-13 are obviously transient. Thus, the progression of liver disease could not be prevented but delayed through prolonged preservation of the biliary epithelium. This observation underlines that epithelial barrier function is crucial for the initiation of hepatic damage in Abcb4−/−; however, the loss of biliary phosphatidylcholine was not compensated by the lack of IL-13.
Recently, it has been demonstrated that IL-13 simultaneously and independently promoted hepatic fibrosis and the biliary reaction to progressive liver disease [52]. The clinical impact of IL-13 and downstream signaling events in chronic liver diseases of different etiologies and fibrosis were recently summarized [22]. Both fibroblasts and biliary cells are directly targeted by IL-13, resulting in the activation of ECM-producing myofibroblasts and concurrent ductular reaction [52]. Therefore, it is likely that reduced fibrosis in 52-week-old Abcb4−/−/IL-13−/− mice is a cumulative effect of delayed parenchymal injury caused by preserved BEC barrier function and decreased activation of ECM-producing myofibroblasts.
Bile acid-induced endoplasmic reticulum stress has been shown to stimulate apoptosis in HepG2 cells in a hydrophobicity- and concentration-dependent manner [53]. In our model, the impact of ER-stress on hepatocyte damage during cholestasis is shown by the phosphorylation of ER-stress-dependent PERK and eIF2α in Abcb4−/− mice, which was reduced by the IL-13−/−-knockout.
In the current study, the global transcript profile of liver tissue revealed that gene expression in Abcb4−/− mice significantly differed from wild type and was almost comparable to controls in Abcb4−/−/IL-13−/− mice: (i) reduced expression of intercellular adhesion molecules in the presence of IL-13 supports the idea that depletion of this cytokine has stabilizing effects on BEC barrier function [54]. (ii) Steroid hormone metabolism was significantly altered in Abcb4−/− mice in comparison to wild type mice and returned to normal in Abcb4−/−/IL-13−/− mice. Furthermore, functional annotation clustering of regulated genes indicated alterations in biological processes that may be involved in ductular integrity and fibrosis. Previous studies demonstrated that retinol and steroid metabolism as well as PPAR signaling pathway might be linked to liver damage in Abcb4−/− mice. Modulation of PPAR- and retinoic acid signaling in clinical and animal studies showed promising results for the therapy of cholangiopathies [55]. Modulation of PPAR alters hyperlipidemia, bile acid metabolism, inflammation, detoxification, and fibrosis [29,55], while all-trans retinoic acids have been shown to regulate cell proliferation, differentiation, and morphogenesis, as well as inflammation in biliary diseases [55,56]. Our study revealed that biochemical conversion of all-trans retinoic acids was differentially regulated in Abcb4−/− as compared to Abcb4−/−/IL-13−/− mice.
It has been assumed that IL-13 is a key effector cytokine in ulcerative colitis and that enterohepatic bile acid circulation is disturbed by BA malabsorption in inflammatory bowel diseases [57,58,59]. Increased luminal bile acid hydrophobicity was associated with cytotoxicity and contributes to gut barrier dysfunction [60], which is also reflected by our current study. Furthermore, in alcohol-induced injury of the gut barrier, augmented secondary BAs were associated with enhanced inflammation of the colonic mucosa [61]. In contrast, IL-13 deficiency caused reduction in secondary fecal bile acids in Abcb4−/− mice, resulting in marginal ileal damage. Although the inflammatory functions of BA have been known for a long time, they are not primary initiators of the pathologies [62]. We assume that the enhanced pathology seen in Abcb4−/− mice is due to mutual interference of hepatic and ileal damage, underlining the enterohepatic relationship in liver injury. Thus, normalization of BA excretion and sustained ileal integrity in Abcb4−/−/IL-13−/− mice preserved the circulation of enterohepatic BA.
Bacterial infections are frequent in cirrhosis and contribute to the progression of chronic liver disease [7]. It has been suggested that cholestasis-associated bacterial translocation may be linked to enhanced levels of intestinal cytokines such as IFN-γ, IL-4, and IL-17 that facilitate the intestinal permeability [63]. Our data point out that the lack of IL-13 reduces bacterial translocation in Abcb4−/− mice. This is in accordance with previous reports showing the need for tight regulation of intestinal Th2 cytokines such as IL-4, but also IL-13, to maintain the intestinal barrier.
In Abcb4−/− mice, but not in Abcb4−/−/IL-13−/− mice, we found in the fecal microbiota enriched OTUs of Prevotella and Oscillibacter, which are both associated with intestinal pathology. Prevotella is overrepresented in the duodenum of cirrhotic patients [64], while increased Oscillibacter was shown to enhance gut permeability in diet-induced obese mice [65]. In contrast, Prevotella and Oscillibacter are known producers of anti-inflammatory metabolites, promoting the differentiation of anti-inflammatory Treg/Tr1 cells in the gut [66]. Surprisingly, in Abcb4−/−/IL-13−/− mice, the genera Prevotella and Oscillobacter were not altered but the taxa Lactobacillus, Roseburia, and Alistipes were overrepresented. Correspondingly, in rats with obstructive jaundice, Lactobacillus has been shown to support hepatic barrier function through maintenance of the structure and function of tight junctions [67]. Of note, while a lack of IL-13 altered the microbial composition, it remains enigmatic whether these changes are directly related to improved hepatic barrier function and integrity. Although the gut microbiome is known to influence the bile acid metabolism [68], bile acids may also influence the composition of the intestinal microbiota directly or indirectly via the activation of the innate immunity [69], demonstrating the crosstalk between bile acids and microbiota [70]. Thus, normalization of serum and fecal bile acid composition in Abcb4−/−IL-13−/− mice might be a direct consequence of the altered gut microbiome. Alternatively, normalized bile excretion might have influenced the composition of the gut microbiome [71]. The most important data of this study were summarized as a graphical abstract (Figure S7).

5. Conclusions

In conclusion, the prolonged liver integrity and normalization of microbial homeostasis demonstrate the therapeutic potential of blocking IL-13. This is the first study showing that IL-13-depletion could be a therapeutic approach for the treatment of patients with bile duct disorders.

Supplementary Materials

The following are available online at https://www.mdpi.com/2073-4409/9/9/1949/s1, Figure S1: Serum alkaline phosphatase levels. Figure S2: Expression of genes responsible for BA synthesis and –transport, Figure S3: IL-13 knockout reduced ER stress, Figure S4: Epithelial proliferation and lymphocyte infiltration, Figure S5: Bacterial translocation to the liver was reduced in Abcb4−/−/IL-13−/−-mice. Figure S6: Graphical abstract.

Author Contributions

Conceptualization, U.S., E.R., and M.R.; methodology, D.H., E.M., E.D., S.O., M.W., T.H., T.R., S.W., H.-J.M., N.S., C.E., Y.C. and R.W.; validation, L.H., M.R. and A.W.; formal analysis, L.H., N.H., D.H., U.D., E.D., S.O., M.W., T.H., H.-J.M., N.S., A.B., Y.C., and A.W.; investigation, L.H., E.D., T.H., H.-J.M., N.S., and M.R.; resources, E.M., E.D., T.H., S.W., H.-J.-M., C.E., and E.R.; data curation, L.H., H.-J.M., and M.R.; writing—original draft preparation, L.H., E.R., and M.R.; writing—review and editing, N.H., D.H., E.M., U.D., E.D., S.O., M.W., T.H., T.R., S.W., H.-J.M., N.S., C.E., A.B., Y.C., A.W., R.W., and U.S.; visualization, L.H., E.D., T.H., and M.R.; supervision, E.R. and M.R.; project administration, M.R.; funding acquisition, M.R., U.S., E.R., D.H., E.M., T.H., E.D., and R.W. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by a grant from the Behring-Roentgen Foundation (#60-0002 to MR and US) and grants from the Deutsche Forschungsgemeinschaft (RO 957/10-1 & RO 957/11 to ER, RO 3714/4 to MR and KFO 217 to DH and EM). The microbiome part of this work was supported by the Deutsche Forschungsgemeinschaft KFO309 Z01, SFB1021 Z02, SFB-TR84 project B08 to TH and the German Center for Infection research (DZIF) to TH and ED. RW is supported by the Deutsche Forschungsgemeinschaft (SFB/TRR57, projects P13 and Q3) and the Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at the RWTH Aachen University (IZKF Aachen, project O3-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

The authors thank P. Fickert (Medical University of Graz, Austria) for helpful suggestions and A. McKenzie and the Medical Research Council (Swindon, UK) for permission to use IL-13−/− mice. The authors thank Annette Tschuschner, Dagmar Leder, Silke Zechel-Gran, and Ina Wagner (MPI for Infection Biology, Berlin) for excellent technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rao, R.K.; Samak, G. Bile duct epithelial tight junctions and barrier function. Tissue Barriers 2013, 1, e25718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Sakisaka, S. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2001, 33, 1460–1468. [Google Scholar] [CrossRef]
  3. Grosse, B.; Cassio, D.; Yousef, N.; Bernardo, C.; Jacquemin, E.; Gonzales, E. Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability. Hepatology 2012, 55, 1249–1259. [Google Scholar] [CrossRef] [PubMed]
  4. Fickert, P.; Fuchsbichler, A.; Wagner, M.; Zollner, G.; Kaser, A.; Tilg, H.; Krause, R.; Lammert, F.; Langner, C.; Zatloukal, K.; et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004, 127, 261–274. [Google Scholar] [CrossRef] [PubMed]
  5. Sasatomi, K.; Noguchi, K.; Sakisaka, S.; Sata, M.; Tanikawa, K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 1998, 29, 409–416. [Google Scholar] [CrossRef]
  6. Williamson, K.D.; Chapman, R.W. Primary sclerosing cholangitis. Dig. Dis. 2014, 32, 438–445. [Google Scholar] [CrossRef]
  7. Konturek, P.C.; Harsch, I.A.; Konturek, K.; Schink, M.; Konturek, T.; Neurath, M.F.; Zopf, Y. Gut-Liver Axis: How Do Gut Bacteria Influence the Liver? Med. Sci. (Basel) 2018, 6, 79. [Google Scholar] [CrossRef] [Green Version]
  8. Reyes, H.; Zapata, R.; Hernández, I.; Gotteland, M.; Sandoval, L.; Jirón, M.I.; Palma, J.; Almuna, R.; Silva, J.J. Is a leaky gut involved in the pathogenesis of intrahepatic cholestasis of pregnancy? Hepatology 2006, 43, 715–722. [Google Scholar] [CrossRef]
  9. Odenwald, M.A.; Turner, J.R. The intestinal epithelial barrier: A therapeutic target? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 9–21. [Google Scholar] [CrossRef]
  10. Tilg, H.; Cani, P.D.; Mayer, E.A. Gut microbiome and liver diseases. Gut 2016, 65, 2035–2044. [Google Scholar] [CrossRef]
  11. Cabrera-Rubio, R.; Patterson, A.M.; Cotter, P.D.; Beraza, N. Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice. Sci. Rep. 2019, 9, 12324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Perez, M.-J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 2009, 15, 1677–1689. [Google Scholar] [CrossRef] [PubMed]
  13. Bessho, K.; Bezerra, J.A. Biliary atresia: Will blocking inflammation tame the disease? Annu. Rev. Med. 2011, 62, 171–185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Bo, X.; Broome, U.; Remberger, M.; Sumitran-Holgersson, S. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001, 49, 131–141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Mano, Y.; Ishii, M.; Okamoto, H.; Igarashi, T.; Kobayashi, K.; Toyota, T. Effect of tumor necrosis factor alpha on intrahepatic bile duct epithelial cell of rat liver. Hepatology 1996, 23, 1602–1607. [Google Scholar] [CrossRef]
  16. Hanada, S.; Harada, M.; Koga, H.; Kawaguchi, T.; Taniguchi, E.; Kumashiro, R.; Ueno, T.; Ueno, Y.; Ishii, M.; Sakisaka, S.; et al. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int. 2003, 23, 3–11. [Google Scholar] [CrossRef]
  17. Müller, T.; Beutler, C.; Picó, A.H.; Otten, M.; Dürr, A.; Al-Abadi, H.; Guckelberger, O.; Zum Meyer Büschenfelde, D.; Jöhrens, K.; Volkmann, M.; et al. Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. Gastroenterology 2013, 144, 1116–1128. [Google Scholar] [CrossRef]
  18. Zen, Y.; Fujii, T.; Harada, K.; Kawano, M.; Yamada, K.; Takahira, M.; Nakanuma, Y. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007, 45, 1538–1546. [Google Scholar] [CrossRef]
  19. Li, J.; Razumilava, N.; Gores, G.J.; Walters, S.; Mizuochi, T.; Mourya, R.; Bessho, K.; Wang, Y.-H.; Glaser, S.S.; Shivakumar, P.; et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J. Clin. Invest. 2014, 124, 3241–3251. [Google Scholar] [CrossRef] [Green Version]
  20. Hammerich, L.; Tacke, F. Interleukins in chronic liver disease: Lessons learned from experimental mouse models. Clin. Exp. Gastroenterol. 2014, 7, 297–306. [Google Scholar] [CrossRef] [Green Version]
  21. Chiaramonte, M.G.; Donaldson, D.D.; Cheever, A.W.; Wynn, T.A. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J. Clin. Invest. 1999, 104, 777–785. [Google Scholar] [CrossRef] [Green Version]
  22. Liu, Y.; Munker, S.; Müllenbach, R.; Weng, H.-L. IL-13 Signaling in liver fibrogenesis. Front. Immunol. 2012, 3, 116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Long, X.; Chen, Q.; Zhao, J.; Rafaels, N.; Mathias, P.; Liang, H.; Potee, J.; Campbell, M.; Zhang, B.; Gao, L.; et al. An IL-13 promoter polymorphism associated with liver fibrosis in patients with Schistosoma japonicum. PLoS ONE 2015, 10, e0135360. [Google Scholar] [CrossRef] [PubMed]
  24. Weng, H.-L.; Liu, Y.; Chen, J.-L.; Huang, T.; Xu, L.-J.; Godoy, P.; Hu, J.-H.; Zhou, C.; Stickel, F.; Marx, A.; et al. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 2009, 50, 230–243. [Google Scholar] [CrossRef] [PubMed]
  25. Churin, Y.; Roderfeld, M.; Stiefel, J.; Würger, T.; Schröder, D.; Matono, T.; Mollenkopf, H.-J.; Montalbano, R.; Pompaiah, M.; Reifenberg, K.; et al. Pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background. PLoS ONE 2014, 9, e90608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. McKenzie, G.J.; Emson, C.L.; Bell, S.E.; Anderson, S.; Fallon, P.; Zurawski, G.; Murray, R.; Grencis, R.; McKenzie, A.N.J. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998, 9, 423–432. [Google Scholar] [CrossRef] [Green Version]
  27. Roderfeld, M.; Rath, T.; Pasupuleti, S.; Zimmermann, M.; Neumann, C.; Churin, Y.; Dierkes, C.; Voswinckel, R.; Barth, P.J.; Zahner, D.; et al. Bone marrow transplantation improves hepatic fibrosis in Abcb4−/− mice via Th1 response and matrix metalloproteinase activity. Gut 2012, 61, 907–916. [Google Scholar] [CrossRef]
  28. Roderfeld, M.; Rath, T.; Voswinckel, R.; Dierkes, C.; Dietrich, H.; Zahner, D.; Graf, J.; Roeb, E. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4−/− mice. Hepatology 2010, 51, 267–276. [Google Scholar] [CrossRef]
  29. Baghdasaryan, A.; Fickert, P.; Fuchsbichler, A.; Silbert, D.; Gumhold, J.; Hörl, G.; Langner, C.; Moustafa, T.; Halilbasic, E.; Claudel, T.; et al. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 2008, 28, 948–958. [Google Scholar] [CrossRef]
  30. García-Cañaveras, J.C.; Donato, M.T.; Castell, J.V.; Lahoz, A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J. Lipid Res. 2012, 53, 2231–2241. [Google Scholar] [CrossRef] [Green Version]
  31. Li, K.; Buchinger, T.J.; Bussy, U.; Fissette, S.D.; Johnson, N.S.; Li, W. Quantification of 15 bile acids in lake charr feces by ultra-high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2015, 1001, 27–34. [Google Scholar] [CrossRef] [PubMed]
  32. Reece, S.T.; Loddenkemper, C.; Askew, D.J.; Zedler, U.; Schommer-Leitner, S.; Stein, M.; Mir, F.A.; Dorhoi, A.; Mollenkopf, H.-J.; Silverman, G.A.; et al. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J. Clin. Invest. 2010, 120, 3365–3376. [Google Scholar] [CrossRef] [PubMed]
  33. Huang, D.W.; Sherman, B.T.; Tan, Q.; Collins, J.R.; Alvord, W.G.; Roayaei, J.; Stephens, R.; Baseler, M.W.; Lane, H.C.; Lempicki, R.A. The DAVID Gene Functional Classification Tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007, 8, R183. [Google Scholar] [CrossRef] [Green Version]
  34. Kanehisa, M.; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28, 27–30. [Google Scholar] [CrossRef] [PubMed]
  35. Irungbam, K.; Churin, Y.; Matono, T.; Weglage, J.; Ocker, M.; Glebe, D.; Hardt, M.; Koeppel, A.; Roderfeld, M.; Roeb, E. Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2. Lab. Invest. 2020, 100, 454–465. [Google Scholar] [CrossRef]
  36. Jamall, I.S.; Finelli, V.N.; Que Hee, S.S. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal. Biochem. 1981, 112, 70–75. [Google Scholar] [CrossRef]
  37. Kozich, J.J.; Westcott, S.L.; Baxter, N.T.; Highlander, S.K.; Schloss, P.D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl. Environ. Microbiol. 2013, 79, 5112–5120. [Google Scholar] [CrossRef] [Green Version]
  38. Caporaso, J.G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F.D.; Costello, E.K.; Fierer, N.; Peña, A.G.; Goodrich, J.K.; Gordon, J.I.; et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 2010, 7, 335–336. [Google Scholar] [CrossRef] [Green Version]
  39. Quast, C.; Pruesse, E.; Yilmaz, P.; Gerken, J.; Schweer, T.; Yarza, P.; Peplies, J.; Glöckner, F.O. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 2013, 41, D590–D596. [Google Scholar] [CrossRef]
  40. Edgar, R.C.; Haas, B.J.; Clemente, J.C.; Quince, C.; Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011, 27, 2194–2200. [Google Scholar] [CrossRef] [Green Version]
  41. Demarez, C.; Hubert, C.; Sempoux, C.; Lemaigre, F.P. Expression of Molecular Differentiation Markers Does Not Correlate with Histological Differentiation Grade in Intrahepatic Cholangiocarcinoma. PLoS ONE 2016, 11, e0157140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Heuman, D.M. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J. Lipid Res. 1989, 30, 719–730. [Google Scholar] [PubMed]
  43. Wang, D.Q.-H.; Tazuma, S.; Cohen, D.E.; Carey, M.C. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: Studies in the gallstone-susceptible mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G494–G502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Billington, D.; Evans, C.E.; Godfrey, P.P.; Coleman, R. Effects of bile salts on the plasma membranes of isolated rat hepatocytes. Biochem. J. 1980, 188, 321–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Palmer, R.H. Bile acids, liver injury, and liver disease. Arch. Intern. Med. 1972, 130, 606–617. [Google Scholar] [CrossRef] [PubMed]
  46. Alaish, S.M.; Smith, A.D.; Timmons, J.; Greenspon, J.; Eyvazzadeh, D.; Murphy, E.; Shea-Donahue, T.; Cirimotich, S.; Mongodin, E.; Zhao, A.; et al. Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host. Gut Microbes 2013, 4, 292–305. [Google Scholar] [CrossRef] [Green Version]
  47. France, M.M.; Turner, J.R. The mucosal barrier at a glance. J. Cell Sci. 2017, 130, 307–314. [Google Scholar] [CrossRef] [Green Version]
  48. Zihni, C.; Mills, C.; Matter, K.; Balda, M.S. Tight junctions: From simple barriers to multifunctional molecular gates. Nat. Rev. Mol. Cell Biol. 2016, 17, 564–580. [Google Scholar] [CrossRef]
  49. Németh, Z.; Szász, A.M.; Somorácz, A.; Tátrai, P.; Németh, J.; Gyorffy, H.; Szíjártó, A.; Kupcsulik, P.; Kiss, A.; Schaff, Z. Zonula occludens-1, occludin, and E-cadherin protein expression in biliary tract cancers. Pathol. Oncol. Res. 2009, 15, 533–539. [Google Scholar] [CrossRef]
  50. Li, J.; Bessho, K.; Shivakumar, P.; Mourya, R.; Mohanty, S.K.; Dos Santos, J.L.; Miura, I.K.; Porta, G.; Bezerra, J.A. Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype. J. Clin. Invest. 2011, 121, 4244–4256. [Google Scholar] [CrossRef]
  51. Song, P.; Zhang, Y.; Klaassen, C.D. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol. Sci. 2011, 123, 359–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Gieseck, R.L.; Ramalingam, T.R.; Hart, K.M.; Vannella, K.M.; Cantu, D.A.; Lu, W.Y.; Ferreira-González, S.; Forbes, S.J.; Vallier, L.; Wynn, T.A. Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and Fibrosis. Immunity 2016, 45, 145–158. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Adachi, T.; Kaminaga, T.; Yasuda, H.; Kamiya, T.; Hara, H. The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury. J. Clin. Biochem. Nutr. 2014, 54, 129–135. [Google Scholar] [CrossRef] [Green Version]
  54. Bazellières, E.; Conte, V.; Elosegui-Artola, A.; Serra-Picamal, X.; Bintanel-Morcillo, M.; Roca-Cusachs, P.; Muñoz, J.J.; Sales-Pardo, M.; Guimerà, R.; Trepat, X. Control of cell-cell forces and collective cell dynamics by the intercellular sdhesome. Nat. Cell Biol. 2015, 17, 409–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Halilbasic, E.; Fuchs, C.; Hofer, H.; Paumgartner, G.; Trauner, M. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow. Dig. Dis. 2015, 33, 149–163. [Google Scholar] [CrossRef]
  56. Cai, S.-Y.; Mennone, A.; Soroka, C.J.; Boyer, J.L. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2−/− mice. J. Pharmacol. Exp. Ther. 2014, 349, 94–98. [Google Scholar] [CrossRef] [Green Version]
  57. Heller, F.; Florian, P.; Bojarski, C.; Richter, J.; Christ, M.; Hillenbrand, B.; Mankertz, J.; Gitter, A.H.; Bürgel, N.; Fromm, M.; et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129, 550–564. [Google Scholar] [CrossRef]
  58. Hruz, P.; Zimmermann, C.; Gutmann, H.; Degen, L.; Beuers, U.; Terracciano, L.; Drewe, J.; Beglinger, C. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 2006, 55, 395–402. [Google Scholar] [CrossRef]
  59. Vítek, L. Bile acid malabsorption in inflammatory bowel disease. Inflamm. Bowel Dis. 2015, 21, 476–483. [Google Scholar] [CrossRef]
  60. Stenman, L.K.; Holma, R.; Forsgård, R.; Gylling, H.; Korpela, R. Higher fecal bile acid hydrophobicity is associated with exacerbation of dextran sodium sulfate colitis in mice. J. Nutr. 2013, 143, 1691–1697. [Google Scholar] [CrossRef] [Green Version]
  61. Kakiyama, G.; Hylemon, P.B.; Zhou, H.; Pandak, W.M.; Heuman, D.M.; Kang, D.J.; Takei, H.; Nittono, H.; Ridlon, J.M.; Fuchs, M.; et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306, G929–G937. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Pavlidis, P.; Powell, N.; Vincent, R.P.; Ehrlich, D.; Bjarnason, I.; Hayee, B. Systematic review: Bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment. Pharmacol. Ther. 2015, 42, 802–817. [Google Scholar] [CrossRef] [PubMed]
  63. Vega-Magaña, N.; Delgado-Rizo, V.; García-Benavides, L.; Del Toro-Arreola, S.; Segura-Ortega, J.; Morales, A.S.M.Z.; Zepeda-Nuño, J.S.; Escarra-Senmarti, M.; Gutiérrez-Franco, J.; Haramati, J.; et al. Bacterial translocation is linked to increased intestinal IFN-γ, IL-4, IL-17, and mucin-2 in cholestatic rats. Ann. Hepatol. 2018, 17, 318–329. [Google Scholar] [CrossRef] [PubMed]
  64. Chen, Y.; Ji, F.; Guo, J.; Shi, D.; Fang, D.; Li, L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci. Rep. 2016, 6, 34055. [Google Scholar] [CrossRef] [PubMed]
  65. Lam, Y.Y.; Ha, C.W.Y.; Campbell, C.R.; Mitchell, A.J.; Dinudom, A.; Oscarsson, J.; Cook, D.I.; Hunt, N.H.; Caterson, I.D.; Holmes, A.J.; et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS ONE 2012, 7, e34233. [Google Scholar] [CrossRef] [Green Version]
  66. Li, J.; Sung, C.Y.J.; Lee, N.; Ni, Y.; Pihlajamäki, J.; Panagiotou, G.; El-Nezami, H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc. Natl. Acad. Sci. USA 2016, 113, E1306–E1315. [Google Scholar] [CrossRef] [Green Version]
  67. Zhang, M.; Wang, X.-Q.; Zhou, Y.-K.; Ma, Y.-L.; Shen, T.-Y.; Chen, H.-Q.; Chu, Z.-X.; Qin, H.-L. Effects of oral Lactobacillus plantarum on hepatocyte tight junction structure and function in rats with obstructive jaundice. Mol. Biol. Rep. 2010, 37, 2989–2999. [Google Scholar] [CrossRef]
  68. Swann, J.R.; Want, E.J.; Geier, F.M.; Spagou, K.; Wilson, I.D.; Sidaway, J.E.; Nicholson, J.K.; Holmes, E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. USA 2011, 108, 4523–4530. [Google Scholar] [CrossRef] [Green Version]
  69. Inagaki, T.; Moschetta, A.; Lee, Y.-K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R.T.; Shelton, J.M.; Richardson, J.A.; Repa, J.J.; et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. USA 2006, 103, 3920–3925. [Google Scholar] [CrossRef] [Green Version]
  70. Wahlström, A.; Sayin, S.I.; Marschall, H.-U.; Bäckhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016, 24, 41–50. [Google Scholar] [CrossRef] [Green Version]
  71. Tian, Y.; Gui, W.; Koo, I.; Smith, P.B.; Allman, E.L.; Nichols, R.G.; Rimal, B.; Cai, J.; Liu, Q.; Patterson, A.D. The microbiome modulating activity of bile acids. Gut Microbes 2020, 11, 979–996. [Google Scholar] [CrossRef] [PubMed]
Cells 09 01949 g001 550
Figure 1. IL-13 knockout restored bile duct architecture in Abcb4−/− mice. (A) Hematoxylin and eosin (H & E)-staining demonstrated loss of lumenization or bile duct collapse (arrowhead), massive proliferation of biliary cells (arrow), thickening of mesenchymal layer (bracket), swelling of biliary epithelial cells (BECs), and altered BEC organization (arrows) in Abcb4−/− mice. In contrast, appearance of BEC and bile duct morphology was preserved in Abcb4−/− mice with IL-13 knockout and biliary architecture were preserved (arrowheads). H & E staining and histological scoring by an expert (U.D.) were performed for all mice in this study (n = 10 per group, 120 sections). (B,C) Immunostaining of CK19 (red) and (B) E-cadherin (green) as well as (C) ZO-1 (green) accentuated structural preservation of distinct biliary cell contacts and sharply stained tight junctions in Abcb4−/−/IL-13−/− mice in comparison to Abcb4−/− mice (arrowheads). Abcb4−/− showed altered tight junction morphology characterized by an altered, partially disrupted, ZO-1 staining pattern between BECs. (D) Ki67 staining (red) indicated proliferation of CK19+-BEC in Abcb4−/− mice (arrowheads). (E) Homogenous staining for BEC-marker Sox9 (red) is almost lost in CK19+ (black) BEC for Abcb4−/− mice but largely preserved in Abcb4−/−/IL-13−/− mice (arrowheads). Immunohistochemistry was performed for 3-4 representative animals per group in 8-week-old animals, 12–16 sections per immunostaining). Representative micrographs are shown. Bars (A,D,E) 50 µm and (B,C) 12 µm, magnification (A,D,E) ×400 and (B,C) ×1000.
Figure 1. IL-13 knockout restored bile duct architecture in Abcb4−/− mice. (A) Hematoxylin and eosin (H & E)-staining demonstrated loss of lumenization or bile duct collapse (arrowhead), massive proliferation of biliary cells (arrow), thickening of mesenchymal layer (bracket), swelling of biliary epithelial cells (BECs), and altered BEC organization (arrows) in Abcb4−/− mice. In contrast, appearance of BEC and bile duct morphology was preserved in Abcb4−/− mice with IL-13 knockout and biliary architecture were preserved (arrowheads). H & E staining and histological scoring by an expert (U.D.) were performed for all mice in this study (n = 10 per group, 120 sections). (B,C) Immunostaining of CK19 (red) and (B) E-cadherin (green) as well as (C) ZO-1 (green) accentuated structural preservation of distinct biliary cell contacts and sharply stained tight junctions in Abcb4−/−/IL-13−/− mice in comparison to Abcb4−/− mice (arrowheads). Abcb4−/− showed altered tight junction morphology characterized by an altered, partially disrupted, ZO-1 staining pattern between BECs. (D) Ki67 staining (red) indicated proliferation of CK19+-BEC in Abcb4−/− mice (arrowheads). (E) Homogenous staining for BEC-marker Sox9 (red) is almost lost in CK19+ (black) BEC for Abcb4−/− mice but largely preserved in Abcb4−/−/IL-13−/− mice (arrowheads). Immunohistochemistry was performed for 3-4 representative animals per group in 8-week-old animals, 12–16 sections per immunostaining). Representative micrographs are shown. Bars (A,D,E) 50 µm and (B,C) 12 µm, magnification (A,D,E) ×400 and (B,C) ×1000.
Cells 09 01949 g001
Cells 09 01949 g002 550
Figure 2. IL-13-knockout reduced serum bile acid concentrations and improved hepatic integrity. (A) IL-13-knockout transiently reduced serum bile acids in Abcb4−/−/IL-13−/− mice. (B) The seven most prominent serum bile acids were significantly reduced in 8-week-old Abcb4−/−/IL-13−/− mice. Wt and IL-13−/− controls n = 3–4, Abcb4−/− and Abcb4−/−/IL-13−/− n = 4–6. Please note the two scale breaks in the y-axis. (C) Serum biochemical parameter of hepatocellular injury (ALT) decreased in Abcb4−/−/IL-13−/− mice of 8 and 26 weeks but adjusted to Abcb4−/−-serum levels at 52 weeks of age. n = 8–12. (D) Serum ALT correlated well to serum bile acid concentrations (8, 26, and 52 weeks). (E) The ratio between secondary and primary serum bile acids was not altered by IL-13 knockout in Abcb4−/− mice at the age of 8 weeks. (F) The hydrophobicity index was normalized in Abcb4−/−/IL-13−/− mice aged 8 weeks. Values are means ± SEM. * p < 0.05 Abcb4−/− vs Abcb4−/−/IL-13−/−. Abbreviations used are: T-BA, taurine conjugated bile acids; wt, wild type.
Figure 2. IL-13-knockout reduced serum bile acid concentrations and improved hepatic integrity. (A) IL-13-knockout transiently reduced serum bile acids in Abcb4−/−/IL-13−/− mice. (B) The seven most prominent serum bile acids were significantly reduced in 8-week-old Abcb4−/−/IL-13−/− mice. Wt and IL-13−/− controls n = 3–4, Abcb4−/− and Abcb4−/−/IL-13−/− n = 4–6. Please note the two scale breaks in the y-axis. (C) Serum biochemical parameter of hepatocellular injury (ALT) decreased in Abcb4−/−/IL-13−/− mice of 8 and 26 weeks but adjusted to Abcb4−/−-serum levels at 52 weeks of age. n = 8–12. (D) Serum ALT correlated well to serum bile acid concentrations (8, 26, and 52 weeks). (E) The ratio between secondary and primary serum bile acids was not altered by IL-13 knockout in Abcb4−/− mice at the age of 8 weeks. (F) The hydrophobicity index was normalized in Abcb4−/−/IL-13−/− mice aged 8 weeks. Values are means ± SEM. * p < 0.05 Abcb4−/− vs Abcb4−/−/IL-13−/−. Abbreviations used are: T-BA, taurine conjugated bile acids; wt, wild type.
Cells 09 01949 g002
Cells 09 01949 g003 550
Figure 3. IL13 knockout reduced hepatic pathology and fibrosis in Abcb4−/− mice. (A–C) Histological scoring revealed an ameliorated total histological score (A) and a reduced number of apoptotic hepatocytes (B) in 8-week-old Abcb4−/−/IL-13−/− mice (p = 0.047 and p = 0.018, respectively), while pathologic assessment of bile duct proliferation failed to reach statistical difference (C). (D) Quantitative assessment of hydroxyproline (HYP) showed reduced hepatic accumulation of fibrillary collagen in 52-week-old Abcb4−/−/IL-13−/− mice, Values are means ± SEM. * p < 0.05 Abcb4−/− vs Abcb4−/−/IL-13−/−. (E) Sirius-red staining demonstrated reduced chicken wire fibrosis along with sinusoids and loosened periportal fibrillar collagen deposition in 52-week-old Abcb4−/−/IL-13−/− mice. Magnification 200 ×, bars 100 µm. (F) Serum ALT correlated well with hepatic HYP content.
Figure 3. IL13 knockout reduced hepatic pathology and fibrosis in Abcb4−/− mice. (A–C) Histological scoring revealed an ameliorated total histological score (A) and a reduced number of apoptotic hepatocytes (B) in 8-week-old Abcb4−/−/IL-13−/− mice (p = 0.047 and p = 0.018, respectively), while pathologic assessment of bile duct proliferation failed to reach statistical difference (C). (D) Quantitative assessment of hydroxyproline (HYP) showed reduced hepatic accumulation of fibrillary collagen in 52-week-old Abcb4−/−/IL-13−/− mice, Values are means ± SEM. * p < 0.05 Abcb4−/− vs Abcb4−/−/IL-13−/−. (E) Sirius-red staining demonstrated reduced chicken wire fibrosis along with sinusoids and loosened periportal fibrillar collagen deposition in 52-week-old Abcb4−/−/IL-13−/− mice. Magnification 200 ×, bars 100 µm. (F) Serum ALT correlated well with hepatic HYP content.
Cells 09 01949 g003
Cells 09 01949 g004 550
Figure 4. Restored bile acid excretion pattern improved ileal integrity. (A) Two of the seven most concentrated bile acids were significantly reduced in the feces of 8-week-old Abcb4−/−/IL-13−/− mice, while the concentration of three bile acids were increased. (B) The ratio of bile acid excretion (feces/serum) was increased 8-fold in 8-week-old Abcb4−/−/IL-13−/− mice. (C,D) The ratios of secondary to primary bile acids (C) and hydrophobicity index (D) of fecal bile acids were reduced in feces of 8-week-old Abcb4−/−/IL-13−/− mice. Values are means ± SEM for n = 5 (Abcb4−/−) and n = 6 (Abcb4−/−/IL-13−/−) for fecal BA analysis. * p < 0.05 Abcb4−/− vs. Abcb4−/−/IL-13−/−. BA bile acid, wt wild type. (E) H&E staining as well as immunostaining for E-cadherin and c-Jun demonstrate blunted and crippled villi (#), loss of goblet cells (arrows), and separation of villus epithelium (*) from underlying lamina propria in Abcb4−/− mice and amelioration of these symptoms in Abcb4−/−/IL-13−/− mice. Note the tremendous loss of E-cadherin and the distinct nuclear c-Jun-staining in epithelia at the tips of villi in Abcb4−/− mice (red arrowheads, middle and lower panels). Magnification 200×, bars 100 µm. Abbreviation: HI hydrophobicity index.
Figure 4. Restored bile acid excretion pattern improved ileal integrity. (A) Two of the seven most concentrated bile acids were significantly reduced in the feces of 8-week-old Abcb4−/−/IL-13−/− mice, while the concentration of three bile acids were increased. (B) The ratio of bile acid excretion (feces/serum) was increased 8-fold in 8-week-old Abcb4−/−/IL-13−/− mice. (C,D) The ratios of secondary to primary bile acids (C) and hydrophobicity index (D) of fecal bile acids were reduced in feces of 8-week-old Abcb4−/−/IL-13−/− mice. Values are means ± SEM for n = 5 (Abcb4−/−) and n = 6 (Abcb4−/−/IL-13−/−) for fecal BA analysis. * p < 0.05 Abcb4−/− vs. Abcb4−/−/IL-13−/−. BA bile acid, wt wild type. (E) H&E staining as well as immunostaining for E-cadherin and c-Jun demonstrate blunted and crippled villi (#), loss of goblet cells (arrows), and separation of villus epithelium (*) from underlying lamina propria in Abcb4−/− mice and amelioration of these symptoms in Abcb4−/−/IL-13−/− mice. Note the tremendous loss of E-cadherin and the distinct nuclear c-Jun-staining in epithelia at the tips of villi in Abcb4−/− mice (red arrowheads, middle and lower panels). Magnification 200×, bars 100 µm. Abbreviation: HI hydrophobicity index.
Cells 09 01949 g004
Cells 09 01949 g005 550
Figure 5. Beneficial change in intestinal microbiome in Abcb4−/−/IL-13−/− mice. Next-generation sequencing demonstrates alterations of the intestinal microbiome (A), while subsequent principle component analysis revealed characteristic and group specific compositions (B). Deleterious bacteria such as Prevotellaceae (C) and Oscillobacter (E) were raised in Abcb4−/− mice and normalized by the additional IL-13−/−, while beneficial microbiota such as Lactobacillae (D) were raised in Abcb4−/−/IL-13−/− mice in comparison to Abcb4−/−. Values are means ± SEM. * p < 0.05 Abcb4−/− vs Abcb4−/−/IL-13−/−.
Figure 5. Beneficial change in intestinal microbiome in Abcb4−/−/IL-13−/− mice. Next-generation sequencing demonstrates alterations of the intestinal microbiome (A), while subsequent principle component analysis revealed characteristic and group specific compositions (B). Deleterious bacteria such as Prevotellaceae (C) and Oscillobacter (E) were raised in Abcb4−/− mice and normalized by the additional IL-13−/−, while beneficial microbiota such as Lactobacillae (D) were raised in Abcb4−/−/IL-13−/− mice in comparison to Abcb4−/−. Values are means ± SEM. * p < 0.05 Abcb4−/− vs Abcb4−/−/IL-13−/−.
Cells 09 01949 g005
Cells 09 01949 g006 550
Figure 6. IL-13 knockout reversed specific intestinal microbiome associations in cholestatic mice. (A–C) Intestinal occurrence of Roseburia, Alistipes, and Incertae Sedis was increased in Abcb4−/−/IL-13−/− mice. Mean ± SEM is depicted, * p < 0.05 was considered significant. (D) Network displays the negative association between Abcb4−/− mice and Roseburia, and Incertae Sedis (green edges) and the positive association (red edges) with Prevotella, and Oscillibacter. In Abcb4−/−/IL-13−/− mice, these associations are in reverse. In addition, Abcb4−/−/IL-13−/− mice are negatively associated with Lachnospira. (E) Heatmap and hierarchical clustering of different mice indicates a high similarity between Abcb4−/− and wildtype mice, due to the decreased occurrence of Roseburia, Alistipes, and Incertae Sedis in Abcb4−/− mice and the increased occurrence of Prevotella, the group of Lachnospiraceae, and Oscillibacter. (F) The biplot clearly shows a distinction between Abcb4−/−/IL-13−/− mice and Abcb4−/− mice.
Figure 6. IL-13 knockout reversed specific intestinal microbiome associations in cholestatic mice. (A–C) Intestinal occurrence of Roseburia, Alistipes, and Incertae Sedis was increased in Abcb4−/−/IL-13−/− mice. Mean ± SEM is depicted, * p < 0.05 was considered significant. (D) Network displays the negative association between Abcb4−/− mice and Roseburia, and Incertae Sedis (green edges) and the positive association (red edges) with Prevotella, and Oscillibacter. In Abcb4−/−/IL-13−/− mice, these associations are in reverse. In addition, Abcb4−/−/IL-13−/− mice are negatively associated with Lachnospira. (E) Heatmap and hierarchical clustering of different mice indicates a high similarity between Abcb4−/− and wildtype mice, due to the decreased occurrence of Roseburia, Alistipes, and Incertae Sedis in Abcb4−/− mice and the increased occurrence of Prevotella, the group of Lachnospiraceae, and Oscillibacter. (F) The biplot clearly shows a distinction between Abcb4−/−/IL-13−/− mice and Abcb4−/− mice.
Cells 09 01949 g006
Table
Table 1. Selected terms from functional annotation clustering of genes more than two-fold regulated in Abcb4−/− and Abcb4−/−/IL-13−/− livers.
Table 1. Selected terms from functional annotation clustering of genes more than two-fold regulated in Abcb4−/− and Abcb4−/−/IL-13−/− livers.
TermCountp-Value *Gene Name
Secondary metabolites biosynthesis, transport, and catabolism18
14		4.9 × 10−9
1.4× 10−7		Cyp17a1, Cyp2b13, Cyp2a22, Cyp2c55, Cyp2c67, Cyp2c68, Cyp2g1, Cyp2c37, Cyp26a1, Cyp26b1, Cyp3a11, Cyp3a16, Cyp3a41b, Cyp3a44, Cyp4a10, Cyp4a12b, Cyp4a12a, Cyp4a31, Cyp4f18, Cyp7a1, Cyp7b1
Extracellular matrix24
26		1.2× 10−9
3.0× 10−13		Adamtsl2, Fras1, Adamts2, Adamts4, Ctsg, Col1a1, Col1a2, Col3a1, Col5a3, Col6a2, Col6a3, Dmbt1, Dpt, Fbn1, Lgals3, Lpl, Lum, Loxl1, Mgp, Mmp12, Mmp13, Mmp2, Mmp3, Mmp7, Mfap4, Mfge8, Slpi, Serpine1, Thbs1, Timp1, Zg16
Retinol metabolism15
11		2.4× 10−7
2.4× 10−5		Ugt2b37, Cyp2b13, Cyp2c55, Cyp2c68, Cyp2c37, Cyp26a1, Cyp26b1, Cyp3a11, Cyp3a16, Cyp3a41b, Cyp3a44, Cyp4a10, Cyp4a12b, Cyp4a12a, Cyp4a31, Dhrs9
PPAR signaling pathway13
8		3.0× 10−6
1.6× 10−3		Adipog, Cyp4a10, Cyp4a12b, Cyp4a12a, Cyp4a31, Cyp7a1, Fabp3, Fabp5, Lpl, Plin1, Ppard, Scd1, Scd3, Ucp1
Muscle contraction9
9		1.2× 10−5
2.4× 10−6		Cacna1s, Lmod3, Myom2, Mybpc1, Myh1, Myh2, Myh4, Myh7, Myl1, Tmod4
Cell adhesion30
23		3.5× 10−5
2.1× 10−4		Cd24a, Frem1, Ajap1, Cdh1, Clstn2, Clstn3, Cgref1, Cx3cl1, Col6a2, Ctgf, Cxadr, Dpt, Emb, Efs, Flrt1, Flrt3, Fbln7, Fblim1, Itga11, Itga8, Itgax, Lamc3, Lamc2, Mfap4, Mfge8, Myh10, Ncam1, Spp1, Siglecf, Sdk1, Svep1, Thbs1, Tinag, Tnfrsf12a, Ttyh1, Vcam1
Steroid hormone biosynthesis12
10		4.1× 10−5
9.3× 10−5		Ugt2b37, Cyp17a1, Cyp2b13, Cyp2c55, Cyp2c68, Cyp2c37, Cyp3a11, Cyp3a16, Cyp3a41b, Cyp3a44, Cyp7a1, Cyp7b1, Hsd3b1, Hsd3b5, Sult1e1
Focal adhesion18
14		3.2× 10−4
4.7× 10−4		Shc2, Actg1, Cav3, Col1a1, Col1a2, Col3a1, Col5a3, Col6a2, Col6a3, Ccnd1, Itga11, Itga8, Jun, Lamc3, Lamc2, Myl2, Pak6, Pdgfa, Spp1, Thbs1
ECM receptor interaction10
10		1.0× 10−3
1.0× 10−4		Col1a1, Col1a2, Col3a1, Col5a3, Col6a2, Col6a3, Itga11, Itga8, Lamc3, Lamc2, Spp1, Thbs1
Chemical carcinogenesis10
8		1.4× 10−3
3.5× 10−3		Ugt2b37, Cyp2b13, Cyp2c55, Cyp2c68, Cyp2c37, Cyp3a11, Cyp3a16, Cyp3a41b, Cyp3a44, Gstt3, Sult2a1
* Upper p-value: Abcb4−/− to wild type, bold: genes regulated in both cluster analyses, lower p-value: IL-13−/− to Abcb4−/−/IL-13−/−.

Share and Cite

MDPI and ACS Style

Hahn, L.; Helmrich, N.; Herebian, D.; Mayatepek, E.; Drebber, U.; Domann, E.; Olejniczak, S.; Weigel, M.; Hain, T.; Rath, T.; et al. IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice. Cells 2020, 9, 1949. https://doi.org/10.3390/cells9091949

AMA Style

Hahn L, Helmrich N, Herebian D, Mayatepek E, Drebber U, Domann E, Olejniczak S, Weigel M, Hain T, Rath T, et al. IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice. Cells. 2020; 9(9):1949. https://doi.org/10.3390/cells9091949

Chicago/Turabian Style

Hahn, Luisa, Nora Helmrich, Diran Herebian, Ertan Mayatepek, Uta Drebber, Eugen Domann, Stefan Olejniczak, Markus Weigel, Torsten Hain, Timo Rath, and et al. 2020. "IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice" Cells 9, no. 9: 1949. https://doi.org/10.3390/cells9091949

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop